Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv

Acta Tropica

Volumn 119, Issue 2-3, 2011, Pages 188-193

  Shakya, Nishi ^a   Sane, Shraddha A ^a   Vishwakarma, Preeti ^a   Bajpai, Preeti ^b   Gupta, Suman ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b INTEGRAL UNIVERSITY   (India)

Author keywords

Immunomodulator; Ketoconazole; Leishmania donovani; Miltefosine; Picroliv; Therapeutic switching

Indexed keywords

HYDROGEN PEROXIDE; KETOCONAZOLE; KUTKIN; MILTEFOSINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

DISEASE TREATMENT; DRUG; EFFICIENCY MEASUREMENT; IMMUNITY; TOXICITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION TEST; MESENTERY LYMPH NODE; METABOLITE; MONOTHERAPY; MOUSE; NONHUMAN; PHAGOCYTOSIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CINNAMATES; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; GLYCOSIDES; HYDROGEN PEROXIDE; IMMUNOLOGIC FACTORS; KETOCONAZOLE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; PHAGOCYTOSIS; PHOSPHORYLCHOLINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RODENT DISEASES; TREATMENT OUTCOME; VANILLIC ACID;

ANIMALIA; LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 79960583699     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.05.017     Document Type: Article

References (30)

1. Arevalo I., Ward B., Miller R. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, immunomodulator. Clinical Infectious Diseases 2001, 33:1847-1851.
2. Bhatnagar S., Guru P.Y., Katiyar J.C., Srivastava R., Mukherjee A., Akhtar M.S., Seth M., Bhaduri A.P. Exploration of antileishmanial activity in heterocycles: results of their in vivo and in vitro bioevaluations. Indian Journal of Medical Research 1989, 89:439-444.
3. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Disease 1999, 179:1485-1494.
4. Croft S.L. Kinetoplastida: new therapeutic strategies. Parasite 2008, 15:522-527.
5. Croft S.L., Sutherland C. Antiprotozoan drugs. Encyclopedia of Life Sciences 2002 2002, John Wiley & Sons, Ltd., www.els.net.
6. Croft S.L., Yardley V. Chemotherapy of leishmaniasis. Current Pharmaceutical Design 2002, 8:319-342.
7. Dalton J.E., Kaye P.M. Immunomodulators: use in combined therapy against leishmaniasis. Expert Review of Anti-infective Therapy 2010, 8:739-742.
8. Dwivedi Y., Rastogi R., Garg N.K., Dhawan B.N. Picroliv and its components kutkoside and picroside I protect liver against galactosamine induced damage in rats. Pharmacology and Toxicology 1992, 71:383-387.
9. Griensven J., Balasegaram M., Meheus F., Alvar J., Lynen L., Boelaert M. Combination therapy for visceral leishmaniasis. The Lancet Infectious Diseases 2010, 10:184-194.
10. Gupta S., Ramesh, Sharma S.C., Shrivastava V.M.L. Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Tropica 2005, 94:41-47.
11. Halim M.A., Alfurayh O., Kalin M.E., Dammas S., Al-Eisa A., Damanhouri G. Successful Treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of Pancreatitis due to stibogluconate. Clinical Infectious Diseases 1993, 16:397-399.
12. Hueso M., Bover J., Seron D., Gil-vernet S., Rufí G., Alsina J., Grinyó J.M. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate cure with ketoconazole and allopurinol. Nephrology Dialysis Transplantation 1999, 14:2941.
13. Llorente S., Gimeno L., Navarro M.J., Moreno S., Rodriguez-Girones M. Therapy of visceral leishmaniasis in renal transplant recipients intolerant to pentavalent antimonials. Transplantation 2000, 70:800.
14. Meheus F., Balasegaram M., Olliaro P., Sundar S., Rijal S., Faiz Md.A., Boelaert M. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Neglected Tropical Diseases 2010, 4:e818. 10.1371/journal.pntd.0000818.
15. Murray H.W., Berman J.D., Wright S.D. Immunotherapy for intracellular L. donovani infection: gamma interferon plus pentavalent antimony. Journal of infectious Disease 1988, 157:973-978.
16. Pandey B.D., Pandey K., Kaneko O., Yanagi T., Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. American Journal of Tropical Medicine and Hygiene 2009, 80:580-582.
17. Porwal S., Chauhan S.S., Chauhan P.M.S., Shakya N., Verma A., Gupta S. Discovery of novel antileishmanial agents in an attempt to synthesize pentamidine-aplysinopsin hybrid molecule. Journal of Medicinal Chemistry 2009, 52:5793-5802.
18. Puri A., Saxena R.P., Guru P.Y., Kulshreshtha D.K., Saxena K.C., Dhawan B.N. Immunostimulant activity of picroliv, the iridoid glycoside fraction of P. kurroa and its protective action against L. donovani infection in hamsters. Planta Medica 1992, 58:528-532.
19. Rajeshkumar N.V., Kuttan R. Inhibition of N-nitrosodiethylamine-induced hepatocarcinogenesis by picroliv. Journal of Experimental and Clinical Cancer Research 2000, 19:459-465.
20. Ray A., Chaudhuri S.R., Majumdar B., Bandyopadhyay S.K. Antioxidant activity of ethanol extract of rhizome of P. kurooa on indomethacin induced gastric ulcer during healing. Indian Journal of Clinical Biochemistry 2002, 17:44-51.
21. Sane S.A., Shakya N., Haq W., Gupta S. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. Journal of Antimicrobial Chemotherapy 2010, 65:1448-1454.
22. Seifert K., Croft S.L. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrobial agents and Chemotherapy 2006, 50:73-79.
23. Seth P., Sundar S.V., Seth R.K., Sidhu G.S., Sharma S.C., Kulshreshtha D.K., Maheshwari R.K. Picroliv modulates antioxidant status and down-regulates AP1 transcription factor after hemorrhage and resuscitation. Shock 2003, 19:203-213.
24. Sharma P., Raghavan S.A.V., Saini R., Dikshit M. Ascorbate-mediated enhancement of reactive oxygen species generation from polymorphonuclear leukocyte: modulatory effect of nitric oxide. Journal of Leukocyte Biology 2004, 75:1070-1078.
25. Shrivastava J.K., Misra A., Sharma P., Srivastava B., Naik S., Dube A. Prophylactic potential of autoclaved L. donovani with BCG against experimental visceral leishmaniasis. Parasitology 2003, 127:107-114.
26. Srinivas N., Palne S., Nishi, Gupta S., Bhandari K. Aryloxy cyclohexyl imidazoles: a novel class of antileishmanial agents. Bioorganic Medicinal Chemistry 2009, 19:324-327.
27. Sundar S., Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian Journal of Medical Research 2006, 123:345-352.
28. Sunduru N., Nishi, Palne S., Chauhan P.M.S., Gupta S. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. European Journal of Medicinal Chemistry 2009, 44:2473-2481.
29. Verma P.C., Vaishali B., Gupta V., Saxena G., Rahman L.U. Pharmacology and chemistry of a potent hepatoprotective compound picroliv isolated from the roots and rhizomes of Picrorhiza kurroa Royle ex Benth (Kutki). Current Pharmaceutical Biotechnology 2009, 10:641-649.
30. Walrand S., Valeix S., Rodriguez C., Ligot P., Chassagne J., Vasson M.P. Flow cytometry study of polymorphonuclear neutrophiloxidative burst: a comparison of three fluorescent probes. Clinica Chimica Acta 2003, 331:103-110.